Stonehouse Jon P's Form 4 filing
Biocryst Pharmaceuticals Inc (BCRX) · filed Feb 2, 2023
- Accession no.
- 0001127602-23-003172
- Filed
- Feb 2, 2023
- Trade date
- Dec 29, 2022-Feb 1, 2023
- Filing delay
- 35 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.04M. It was filed 35 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Stonehouse Jon PCIK 0001385496 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 29, 2022 | Common Stock | GGiftDisposed | −10,000 | $0.00 | $0 | 1,008,739 | Direct | |
| Dec 29, 2022 | Common Stock | GGiftAcquired | +5,000 | $0.00 | $0 | 10,000 | Indirect | |
| Dec 29, 2022 | Common Stock | GGiftAcquired | +5,000 | $0.00 | $0 | 10,000 | Indirect | |
| Feb 1, 2023 | Common Stock | MOption exerciseAcquired | +100,000 | $5.45 | +$545,000 | 1,108,739 | Direct | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −100,000 | $10.38 | −$1,038,000 | 1,008,739 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2023 | Common Stock | MOption exerciseDisposed | −100,000 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.